שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

bgp products gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcio chloridum dihydricum, magnesio chloridum hexahydricum, il resto: ovalbuminum max. 0,1 µg, formaldehydum e cetrimidum e polysorbatum 80 e gentamicinum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b ), haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lignaggio)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b ) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/brisbane/60/2008 (victoria lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

איטליה - איטלקית - Ministero della Salute

ssl healthcare italia s.p.a. - calze e gambali compressivi

איטליה - איטלקית - Ministero della Salute

pneumed gmbh luftbetriebene medizinaltechnik - strumentazione varia fisioterapia e riabilitazione- componenti accessori hardware

איטליה - איטלקית - Ministero della Salute

hongkong everbright industrial group co ltd - guanti non chirurgici in vinile

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

glaxosmithkline s.p.a. - influenza, antigene purificato - influenza, antigene purificato

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

seqirus s.r.l. - influenza, antigene purificato - influenza, antigene purificato

איטליה - איטלקית - Ministero della Salute

htrd group hong kong limited - sistemi per trazioni

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

sanofi pasteur - influenza, antigene purificato - influenza, antigene purificato

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ), haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - vaccini